Title : Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.

Pub. Date : 2013 Jun

PMID : 23313065






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inotuzumab ozogamicin (IO) is a CD22 monoclonal antibody attached to calicheamycin that targets B lymphocytes in early stages of development, successfully inducing remission in patients with multiply relapsed ALL. io CD22 molecule Homo sapiens